



**What's New**

**08.03.2019**

**NPPA Revises MRP of select Non-Scheduled Anti-Cancer Medicines w.e.f.  
08.03.2019**

Invoking paragraph 19 of DPCO, 2013, the Government has put a cap on trade margin of 30% on selling price for the select Non-Scheduled Anti-Cancer Drugs containing any of the 42 drugs listed thereof and directed manufacturers to fix their retail price based on price at first point of sale of product.

The NPPA had directed manufacturers to fix their retail price based on price at first point of sale of product (referred as Price to Stockist), as per formula in Table of the aforesaid Order, of the non-scheduled formulations containing any of the 42 Non-Scheduled Anti-Cancer Drugs listed thereof (whether individual or in combination, irrespective of dosage strength, dosage form and /or route of administration).

The NPPA also directed manufacturers to provide the revised MRP of their formulations in Annexure I (Details of PTS and MRP arrived for formulations by using the formula prescribed) of Order dated 27.02.2019 in respect of the non-scheduled formulations containing drugs as per Table B, irrespective whether there was any change in MRP or not, by 6<sup>th</sup> March 2019, under paragraph 9(2) of the DPCO 2013.

NPPA further sought information from 10 Hospitals regarding these 42 drugs, to capture institutional data.

Accordingly, the revised MRP in respect of formulations has been arrived from these 42 drugs as per data provided by manufacturers and is attached herewith as Annexure X.

These revised prices shall come into effect from 8<sup>TH</sup> March, 2019.

Click here

for

[Office Memorandum dated 08.03.2019](#)

[Annexure X](#)

